IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 1566 
Small font sizeDefault font sizeIncrease font size
Navigate Here
Resource Links
 »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »  Article in PDF (155 KB)
 »  Citation Manager
 »  Access Statistics
 »  Reader Comments
 »  Email Alert *
 »  Add to My List *
* Registration required (free)

In This Article
 »  References

 Article Access Statistics
    PDF Downloaded188    
    Comments [Add]    
    Cited by others 2    

Recommend this journal


 Table of Contents    
Year : 2011  |  Volume : 43  |  Issue : 2  |  Page : 219

Buclizine is back again! This time as a pediatric appetite stimulant

Department of Pediatrics, Sri Lakshmi Narayana Institute of Medical Sciences, (SLIMS), Pondicherry, India

Date of Web Publication6-Mar-2011

Correspondence Address:
Thirunavukkarasu Arun Babu
Department of Pediatrics, Sri Lakshmi Narayana Institute of Medical Sciences, (SLIMS), Pondicherry
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0253-7613.77383

Rights and Permissions

How to cite this article:
Babu TA. Buclizine is back again! This time as a pediatric appetite stimulant. Indian J Pharmacol 2011;43:219

How to cite this URL:
Babu TA. Buclizine is back again! This time as a pediatric appetite stimulant. Indian J Pharmacol [serial online] 2011 [cited 2023 Dec 9];43:219. Available from: https://www.ijp-online.com/text.asp?2011/43/2/219/77383


Buclizine is an antihistaminic drug which has been tried in several medical conditions with few or no success. These include motion sickness, allergic conditions, vomiting, migraine, diabetes, insomnia, etc. [1],[2] Recently, we came across a campaign by a well-known pharmaceutical company for this forgotten drug, for an entirely different indication. The syrup formulation of this drug is being promoted as an incredible appetite stimulant for weight gain in children. Although this drug was introduced for this indication a few years back, it was not extensively marketed until earlier this year. The representatives issued a promotional literature containing scientific evidence in support of using this drug. The pamphlet mentioned three trials including the one which compares the weight gain due to cyproheptadine. All the three trials were underpowered with doubtful methodology and exaggerated claims and the most recent one of them was published in the year 1991. [3],[4] No articles were published from indexed journals. There were no trials conducted thereafter for almost 20 years now.

We did an unbiased literature search to check if buclizine is really indicated for this purpose. A Pubmed search revealed no published articles on buclizine and weight gain in the last 40 years, and only a very few before 1970, mostly untraceable non-English articles. [5] None of the standard textbooks of Pharmacology mentioned that this drug is indicated for appetite stimulation. We concluded that there is no convincing literature regarding the use of this drug.

There are few questions to be answered. Do children require appetite stimulant at all? This is still a matter of debate, but most authors do not accept using appetite stimulants routinely for all children to enhance growth. Even in children with failure to thrive, appetite stimulants are never a management option. [6] Is the available proof enough to market this drug? Though Buclizine has been used for this indication for some years now, the current spurt in promotional activity may be due to a recent change in brand's ownership. By any standards of evidence-based medicine, the currently available evidence is grossly insufficient to recommend its use. Why were no trials conducted recently? On what basis the Drugs Controller General of India (DCGI) would have approved this drug? Buclizine has been licensed for marketing in India long time back probably for another indication. This is being misused now, as the marketing approvals were not indication specific during that time. Though DCGI has no further role here as the drug is already marketed, it does however have the moral authority to check irrational and exaggerated claims.

Since most of the mothers complain about their child's weight in spite of normal weight gain, prescriptions of drugs like buclizine are likely to increase. In addition, there is a risk of this drug being used "over the counter." Evidence from large-scale multicentric randomized controlled clinical trials are needed before this drug can be used as a pediatric appetite stimulant. Until then the onus is on the prescribing doctor to decide if the available evidence justifies use of pediatric appetite stimulants in general and buclizine in particular.

 » References Top

1.Adam EI. A treatment for the acute migraine attack. J Int Med Res 1987;15:71-5.  Back to cited text no. 1
2.Durham MP. Clinical trial of buclizine hydrochloride for vomiting of pregnancy. Br Med J 1956;2:1276-7.   Back to cited text no. 2
3.Devare ST, Joglekar GV. Effect of Buclizine on weight. J Ind Med Prof 1968;15:6664-6.   Back to cited text no. 3
4.Dhoble V, Phadke MA. Role of Buclizine hydrochloride in Promoting weight gain in Children. Indian Pract 1991;34:142-9.  Back to cited text no. 4
5.Higa J, Micelli I, Astolfi E. Buclizine as an appetite stimulant. Clinical, experimental and toxicological studies. Prensa Med Argent 1969;56:1129-33.   Back to cited text no. 5
6.Bauchner H. Failure to Thrive. In: Kliegman RM, Behrman RE, Jenson HB, Stanton BF, editors. Nelson Textbook of Pediatrics.18 th ed. Philadelphia: Saunders; 2007. p. 184-7.  Back to cited text no. 6

This article has been cited by
1 DARK Classics in Chemical Neuroscience: Bucinnazine
Karissa Resnik, Pedro Brandão, Emanuele Amorim Alves
ACS Chemical Neuroscience. 2021; 12(19): 3527
[Pubmed] | [DOI]
2 Buclizine crystal forms: First Structural Determinations, counter-ion stoichiometry, hydration, and physicochemical properties of pharmaceutical relevance
Monalisa Bitencourt, Olimpia Maria Martins Santos Viana, Andre Luiz Machado Viana, Jennifer Tavares Jacon Freitas, Cristiane Cabral de Melo, Antonio Carlos Doriguetto
International Journal of Pharmaceutics. 2020; 589: 119840
[Pubmed] | [DOI]


Print this article  Email this article


Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer | Privacy Notice
Online since 20th July '04
Published by Wolters Kluwer - Medknow